Improving Treatments - Improving Lives

Veloxis Pharmaceuticals (Veloxis) is a speciality pharmaceutical company focused on the development and commercialization of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients. All clinical studies for Envarsus®, including two Phase III trials, have successfully been completed and a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in December 2013 seeking approval for the marketing and sale of Envarsus®. Envarsus® has been granted Orphan Drug Status by the FDA.


Aug 21, 2014
Presentation of Interim Report for the 2nd Quarter

PDF Q2 2014 Interim Report
 750.8 KB   Add to Briefcase
PDF Q2 2014 Presentation
 485.8 KB   Add to Briefcase
Webcast Q2 2014 Audiocast

To access the live conference call 14.00 CET, please dial one of the following numbers:

+45 32 72 80 18 (Denmark)
+44 (0) 1452 555 131 (UK)
+1 866 682 8490 (USA)
Access code 89298792

Aug 20, 2014
Interim Report for the 2nd Quarter — for the period 1 January to 30 June, 2014

Stock Information